On May 8, 2025, Dogwood Therapeutics, Inc. announced financial results for the first quarter of 2025 and provided a business update. The company recently commenced a Phase 2b trial of Halneuron for the treatment of Chemotherapy Induced Neuropathic Pain (CINP). An interim data readout is expected in the fourth quarter of 2025. A recent $4.8 million capital raise, together with existing cash, is expected to finance operations through the first quarter of 2026. Dogwood is continuing to explore external funding and/or partnerships to advance IMC-2 into Phase 2b development as a treatment for Long Covid and IMC-1 as a treatment for fibromyalgia.
